Ian J. Witterick

Ian J. Witterick

Auto-generated profile, based on publicly available information

Ian J. Witterick

Joseph and Mildred Sonshine Family Centre for Head and Neck Diseases, Mount Sinai Hospital, Toronto, ON, M5G 1X5, Canada

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2005 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
AVAllan Vescan
Allan Vescan
IWIan Witterick
Ian Witterick
JFJeremy Freeman
Jeremy Freeman

24 November 2010 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
NWNikolaus E. Wolter
Nikolaus E. Wolter
Eng OoiEng Ooi
Eng Ooi
IWIan J. Witterick
Ian J. Witterick

1 January 2016 in Journal of Otolaryngology - Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
CCChristopher J. Chin
Christopher J. Chin
BRBrian Rotenberg
Brian Rotenberg
IWIan J. Witterick
Ian J. Witterick
Patients with Hereditary Hemorrhagic Telangiectasia (HHT) frequently present with epistaxis. Up to 98 % of these patients will have epistaxis at some point in their life. There are multiple ways to deal with this problem, including conservative, medical and surgical options. We present a case and an update on the treatment options for HHT, with a focus on the newer and experimental techniques.


9 July 2012 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
JAJohn R. de Almeida
John R. de Almeida
AVAllan D. Vescan
Allan D. Vescan
PGPatrick J. Gullane
Patrick J. Gullane
FGFred Gentili
Fred Gentili
JLJohn M. Lee
John M. Lee
IWIan J. Witterick
Ian J. Witterick

16 January 2015 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
MKManish Kumar
Manish Kumar
GSGunjan Srivastava
Gunjan Srivastava
JKJatinder Kaur
Jatinder Kaur
JAJasmeet Assi
Jasmeet Assi
AAAkram Alyass
Akram Alyass
RRRanju Ralhan
Ranju Ralhan
Oral squamous cell carcinoma (OSCC) patients are at high risk of loco-regional recurrence and 5-year survival rates are about 50%. Identification of patients at high risk of recurrence will enable rigorous personalized post-treatment management. Most novel biomarkers have failed translation for clinical use because of their limited successful validation in external patient cohorts. The aim of this study was to determine the prognostic significance of alterations in sub-cellular expression of S100A2, a pro-tumorigenic calcium binding protein, identified as a candidate biomarker in our proteomic analysis in OSCC and validation of its clinical utility in an external cohort. In a retrospective study, immunohistochemical analysis of S100A2 was carried out in 235 Indian OSCC (Test set) and 129 normal oral tissues, correlated with clinicopathological parameters and disease outcome over 122 months for OSCC patients following the REMARK criteria. The findings were validated in an external cohort (Validation set 115 Canadian OSCC and 51 normal tissues) and data analyzed using the R package. Significant increase in cytoplasmic and decrease in nuclear S100A2 expression was observed in OSCC in comparison with normal tissues. Cox multivariable regression analysis internally and externally validated cytoplasmic S100A2 association with tumor recurrence. Kaplan Meier analysis of patients stratified to high and low risk groups showed significantly different recurrence free survival (Test set- log rank test, p = 0.005, median survival 16 and 69 months respectively and Validation set - p < 0.00001, median survival 9.4 and 59.9 months respectively); 86% and 81% of patients who had recurrence were correctly stratified into the high risk group. Seventy percent and 81% patients stratified into low risk group did not show cancer recurrence within 1 year in Test and Validation sets. Our study provided clinical evidence for the potential of cytoplasmic S100A2 overexpression as a predictor of recurrence risk in OSCC patients. A unique translational aspect of our study is validation of S100A2 as prognostic marker in two independent cohorts (Canadian and Indian) suggesting this protein is likely to find widespread utility in clinical practice for identifying oral cancer patients at high risk of disease recurrence.